Marcus A Bachhuber1, Cole Thompson2, Ann Prybylowski2, José Benitez3, Silvana Mazzella3, David Barclay3. 1. a Division of General Internal Medicine, Department of Medicine , Montefiore Medical Center/Albert Einstein College of Medicine , Bronx , New York , USA. 2. b Perelman School of Medicine at the University of Pennsylvania , Philadelphia , Pennsylvania , USA. 3. c Prevention Point Philadelphia , Philadelphia , Pennsylvania , USA.
Abstract
BACKGROUND: Syringe exchange programs are uniquely positioned to offer treatment services to interested clients. Prevention Point Philadelphia recently expanded to offer buprenorphine maintenance treatment through its Stabilization, Treatment, and Engagement Program (STEP). OBJECTIVE: To describe the STEP model of care and report treatment outcomes. METHODS: Retrospective chart review of patients enrolled in STEP (October 2011-August 2014). Our main outcome measure was time retained in treatment, defined as time from treatment initiation to treatment failure. Secondary outcome measures were buprenorphine and opiate use, from urine toxicology screens. We analyzed retention in treatment using Kaplan-Meier survival estimates; patients who remained in treatment at the end of the study period were censored on that day. For buprenorphine and opiate use, we calculated the percentage of patients who were positive for buprenorphine and opiates in each month of treatment. RESULTS: Of the 124 patients enrolled in STEP, the median age was 41 (range 21 to 63) and 80% reported injection heroin use. Comorbidities were common: 33% had HIV infection, most reported anxiety (78%) or depression (71%), and 20% were homeless. The most common program outcomes were unplanned self-discharge (n = 29; 23%), incarceration (n = 20; 16%), and administrative discharge (n = 19; 15%). The percentage of patients retained in treatment at 3, 6, 9, and 12 months was 77%, 65%, 59%, and 56%, respectively. Among those retained, the percentage with a positive buprenorphine screen at 3, 6, 9, and 12 months was 88%, 100%, 96%, and 95%, respectively. The percentage with a positive opiates screen was 19%, 13%, 17%, and 16%, respectively. CONCLUSIONS: With a program that blended organizational and community resources, retention in buprenorphine maintenance treatment was comparable to retention rates reported from other settings. Further research should directly compare treatment outcomes in syringe exchange program-based settings versus primary care and specialty settings.
BACKGROUND: Syringe exchange programs are uniquely positioned to offer treatment services to interested clients. Prevention Point Philadelphia recently expanded to offer buprenorphine maintenance treatment through its Stabilization, Treatment, and Engagement Program (STEP). OBJECTIVE: To describe the STEP model of care and report treatment outcomes. METHODS: Retrospective chart review of patients enrolled in STEP (October 2011-August 2014). Our main outcome measure was time retained in treatment, defined as time from treatment initiation to treatment failure. Secondary outcome measures were buprenorphine and opiate use, from urine toxicology screens. We analyzed retention in treatment using Kaplan-Meier survival estimates; patients who remained in treatment at the end of the study period were censored on that day. For buprenorphine and opiate use, we calculated the percentage of patients who were positive for buprenorphine and opiates in each month of treatment. RESULTS: Of the 124 patients enrolled in STEP, the median age was 41 (range 21 to 63) and 80% reported injection heroin use. Comorbidities were common: 33% had HIV infection, most reported anxiety (78%) or depression (71%), and 20% were homeless. The most common program outcomes were unplanned self-discharge (n = 29; 23%), incarceration (n = 20; 16%), and administrative discharge (n = 19; 15%). The percentage of patients retained in treatment at 3, 6, 9, and 12 months was 77%, 65%, 59%, and 56%, respectively. Among those retained, the percentage with a positive buprenorphine screen at 3, 6, 9, and 12 months was 88%, 100%, 96%, and 95%, respectively. The percentage with a positive opiates screen was 19%, 13%, 17%, and 16%, respectively. CONCLUSIONS: With a program that blended organizational and community resources, retention in buprenorphine maintenance treatment was comparable to retention rates reported from other settings. Further research should directly compare treatment outcomes in syringe exchange program-based settings versus primary care and specialty settings.
Authors: Christopher M Jones; Melinda Campopiano; Grant Baldwin; Elinore McCance-Katz Journal: Am J Public Health Date: 2015-06-11 Impact factor: 9.308
Authors: Chinazo O Cunningham; Angela Giovanniello; Xuan Li; Hillary V Kunins; Robert J Roose; Nancy L Sohler Journal: J Subst Abuse Treat Date: 2011-02-18
Authors: Aaron D Fox; Matthew R Anderson; Gary Bartlett; John Valverde; Joanna L Starrels; Chinazo O Cunningham Journal: J Health Care Poor Underserved Date: 2014-08
Authors: Chinazo O Cunningham; Robert J Roose; Joanna L Starrels; Angela Giovanniello; Nancy L Sohler Journal: J Addict Med Date: 2013 Jul-Aug Impact factor: 3.702
Authors: Elenore Patterson Bhatraju; Ellie Grossman; Babak Tofighi; Jennifer McNeely; Danae DiRocco; Mara Flannery; Ann Garment; Keith Goldfeld; Marc N Gourevitch; Joshua D Lee Journal: Addict Sci Clin Pract Date: 2017-02-28
Authors: Shashi N Kapadia; Judith L Griffin; Justine Waldman; Nicolas R Ziebarth; Bruce R Schackman; Czarina N Behrends Journal: Subst Use Misuse Date: 2021-12-10 Impact factor: 2.164
Authors: Andrea Jakubowski; Brianna L Norton; Benjamin T Hayes; Brent E Gibson; Christine Fitzsimmons; L Synn Stern; Franklin Ramirez; Mercedes Guzman; Susan Spratt; Pia Marcus; Aaron D Fox Journal: J Addict Med Date: 2021-11-12 Impact factor: 4.647
Authors: Benjamin T Hayes; Andrea Jakubowski; Christine Fitzsimmons; Billy Garcia; Franklin Ramirez; Aaron D Fox Journal: Subst Use Misuse Date: 2021-05-03 Impact factor: 2.164
Authors: Kristi Hill; Laura Nussdorf; Julia D Mount; Rachel Silk; Chloe Gross; David Sternberg; Phyllis Bijole; Miriam Jones; Randy Kier; Dana Mccullough; Poonam Mathur; Shyam Kottilil; Henry Masur; Sarah Kattakuzhy; Elana S Rosenthal Journal: J Addict Med Date: 2022 Jan-Feb 01 Impact factor: 3.702
Authors: Alexis M Roth; Nguyen K Tran; Marisa Felsher; Annette B Gadegbeku; Brogan Piecara; Rachel Fox; Douglas S Krakower; Scarlett L Bellamy; K Rivet Amico; Jose A Benitez; Barbara Van Der Pol Journal: J Acquir Immune Defic Syndr Date: 2021-03-01 Impact factor: 3.771
Authors: Marcus Castillo; Margaret E C Ginoza; Tyler S Bartholomew; David W Forrest; Costaki Greven; David P Serota; Hansel E Tookes Journal: Harm Reduct J Date: 2020-06-01